Palo Alto Investors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001306923

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 52 positions · Total reported value $723.72M · Top-10 concentration 61.3% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 51.8% · 4 new · 25 cut · 0 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -2.7% · vs SPY -4.8% · Prev Value $723.72M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.2% · vs SPY -5.3% · Latest Value $672.15M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Palo Alto Investors LP disclosed 52 equity positions with a combined reported value of $723.72M. The filing implies a focused portfolio: its ten largest positions account for 61.3% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PTCT ($74.95M), ACAD ($72.46M), INSM ($44.14M). By sector, the heaviest allocations are Health Care 99.7%, Financials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+2.4pp) and away from Other (-2.5pp).

Versus the prior quarter, Palo Alto Investors LP opened 4 new positions, trimmed 25 and fully exited 0, a turnover rate of 51.8% of positions. The portfolio's overlap with the prior quarter was 91% of names.

The largest new positions opened in Q2 2026 were TRAX ($12.14M), SGMT ($1.93M), NAMS ($1.50M).

Of the 2 positions fully exited versus the prior quarter, the largest were FOLD ($16.09M), DNLI ($4.50M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • TRAX FIRST TRACKS BIOTHERAPEUTICS · $12.14M
  • SGMT SAGIMET BIOSCIENCES INC · $1.93M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · $1.50M

Fully Exited (vs previous quarter)

  • FOLD AMICUS THERAPEUTIC · prev qtr: $16.09M
  • DNLI DENALI THERAPEUTICS INC · prev qtr: $4.50M

Insider Transactions (Form 4)

Latest Palo Alto Investors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Palo Alto Investors LP, based in Palo Alto, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 56 positions worth $672.15M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: PALO ALTO, CA, United States
  • SEC registration: 801-58166 (status: Approved), registered 2000-12-05
  • Regulatory AUM (Form ADV): $696.00M as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 6 hedge funds
  • Website: pa-investors.com

Portfolio Structure

  • 56 positions · $672.15M reported value (Q3 2026)
  • Top 10 holdings = 59.9% of reported value
  • Largest position: PTCT (PTC THERAPEUTICS INC) at 8.4%
  • Average position size: $12.00M

Sector Tilt

  • Health Care 99.8%
  • Financials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 4 new, 10 added, 25 reduced
  • 17 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The rebalancing in the second quarter of 2026 appears to be conservative, with a slight preference for maintaining positions rather than making significant changes. The fund's actions suggest a cautious approach to market volatility. 2. Key Moves: - Added: MIRM (MIRUM PHARMACEUTICALS INC) and IRON (DISC MEDICINE INC), indicating a potential interest in smaller biotech companies with growth potential. - Reduced: ANAB (ANAPTYSBIO INC), which could reflect a reevaluation of the company's prospects or a shift in focus within the health care sector. - No Change: The majority of holdings were held steady, with slight adjustments in share count. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be more passive, with a focus on maintaining existing positions rather than actively seeking out new opportunities. - Sector Bias: The health care sector is the primary focus, with no significant diversification into other sectors. - Risk Appetite: The risk appetite is moderate, with a preference for stability and steady growth rather than aggressive growth or high-risk investments. 4. Per-Holding One-Liner: - PTCT: PTC THERAPEUTICS INC - Develops and commercializes innovative oncology and rare disease therapies. - ACAD: ACADIA PHARMACEUTICALS INC - Focuses on innovative medicines for neurological and psychiatric diseases. - INSM: INSMED INC - Develops and commercializes therapies for rare genetic disorders. - MIRM: MIRUM PHARMACEUTICALS INC - Focuses on developing therapies for orphan diseases, including oncology. - ANAB: ANAPTYSBIO INC - Develops novel therapies for neurological and psychiatric disorders. - BMRN: BIOMARIN PHARMACEUTICAL INC - Develops and commercializes novel therapies for rare genetic diseases. - DYN: DYNE THERAPEUTICS INC - Focuses on developing treatments for cancer and other serious diseases. - UTHR: UNITED THERAPEUTICS CORP DEL - Develops and commercializes novel therapies for serious diseases. - IRON: DISC MEDICINE INC - Develops therapies for rare genetic disorders. - BIIB: BIOGEN INC - Focuses on developing therapies for neurological and neurodegenerative diseases. 5. One-Sentence Style Summary: Palo Alto Investors LP maintained a conservative stance in Q2 2026, focusing on health care sector stability with a slight inclination towards biotech companies with growth potential.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.7%
Financials 0.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 918.85K $74.95M 10.36%
10.36%
Hold
2 2.86M $72.46M 10.01%
10.01%
Hold
3 413.98K $44.14M 6.10%
6.10%
Hold
4 348.81K $40.83M 5.64%
5.64%
Add
5 603.49K $40.74M 5.63%
5.63%
Reduce
6 682.78K $39.07M 5.40%
5.40%
Hold
7 1.65M $36.59M 5.06%
5.06%
Hold
8 62.59K $33.91M 4.69%
4.69%
Hold
9 416.65K $30.47M 4.21%
4.21%
Add
10 140.28K $30.31M 4.19%
4.19%
Hold
11 5.30M $22.03M 3.04%
3.04%
Reduce
12 596.50K $19.92M 2.75%
2.75%
Hold
13 1.28M $19.40M 2.68%
2.68%
Hold
14 864.99K $18.91M 2.61%
2.61%
Hold
15 2.95M $16.83M 2.33%
2.33%
Hold
16 550.41K $16.34M 2.26%
2.26%
Hold
17 531.87K $15.16M 2.10%
2.10%
Hold
18 399.86K $14.88M 2.06%
2.06%
Add
19 5.83M $12.77M 1.76%
1.76%
Add
20 242.56K $12.71M 1.76%
1.76%
Hold
21 603.49K $12.14M 1.68%
1.68%
New
22 1.14M $11.19M 1.55%
1.55%
Reduce
23 167.53K $9.52M 1.31%
1.31%
Reduce
24 1.39M $9.48M 1.31%
1.31%
Hold
25 1.61M $8.54M 1.18%
1.18%
Hold
26 213.60K $7.93M 1.09%
1.09%
Hold
27 229.76K $5.53M 0.76%
0.76%
Hold
28 31.39K $5.29M 0.73%
0.73%
Reduce
29 33.55K $3.19M 0.44%
0.44%
Reduce
30 51.34K $3.10M 0.43%
0.43%
Hold
31 18.12K $3.05M 0.42%
0.42%
Hold
32 33.64K $3.04M 0.42%
0.42%
Hold
33 84.63K $2.77M 0.38%
0.38%
Hold
34 32.20K $2.74M 0.38%
0.38%
Hold
35 864.28K $2.60M 0.36%
0.36%
Reduce
36 1.48M $2.21M 0.30%
0.30%
Hold
37 39.60K $2.16M 0.30%
0.30%
Hold
38 250.00K $1.93M 0.27%
0.27%
New
39 326.61K $1.86M 0.26%
0.26%
Reduce
40 19.61K $1.83M 0.25%
0.25%
Hold
41 115.62K $1.64M 0.23%
0.23%
Hold
42 3.98K $1.58M 0.22%
0.22%
Hold
43 44.36K $1.50M 0.21%
0.21%
New
44 309.69K $1.18M 0.16%
0.16%
Add
45 1.79K $959.53K 0.13%
0.13%
Hold
46 24.50K $901.60K 0.12%
0.12%
Hold
47 201.89K $856.01K 0.12%
0.12%
Hold
48 104.41K $826.93K 0.11%
0.11%
Hold
49 108.86K $672.79K 0.09%
0.09%
Hold
50 8.77K $391.32K 0.05%
0.05%
Hold

FAQ

What did Palo Alto Investors LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Palo Alto Investors LP reported 52 equity positions worth $723.72M in aggregate; its largest disclosed positions were PTCT ($74.95M), ACAD ($72.46M), INSM ($44.14M).

How large is Palo Alto Investors LP's portfolio?

Palo Alto Investors LP reported $723.72M of long equity holdings across 52 positions as of 2026-Q2. Top-10 holdings account for 61.3% of reported value.

What is Palo Alto Investors LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/palo-alto-investors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →